RESUMEN
INTRODUCTION: Exercise-induced arterial hypoxemia (EIAH) has been observed in highly trained endurance athletes during near maximal exercise, which may be influenced by a histamine-mediated inflammatory response at the pulmonary capillary-alveolar membrane. In order to test this hypothesis, we examined whether the mast cell stabilizer nedocromil sodium (NS) and H1 -receptor antagonist diphenhydramine HCL (DH) would ameliorate EIAH and mitigate the drop in arterial oxyhemoglobin saturation (Sa O2 ) during intensive exercise. METHODS: Seven highly trained male cross country runners (age, 21 ± 2 years; VÌO2max , 74.7 ± 3.5 ml·kg-1 ·min-1 ) participated in the study. All subjects completed a maximal exercise treadmill test to exhaustion, followed by three 5-min constant-load exercise bouts at 70%, 80%, and 90% VÌO2max . Prior to testing, subjects received either placebo (PL), NS, or DH. RESULTS: Compared to PL, there was a significant treatment effect on Sa O2 (p < 0.001) for both NS and DH during both constant-load exercise and at VÌO2max . Post hoc tests revealed Sa O2 values, compared to PL, were significantly higher at VÌO2max and during DH trials and higher with NS at constant-load intensities except at 70% (p = 0.13). CONCLUSION: The findings provide further evidence that histamine contributes directly or indirectly to the development of EIAH during intense exercise in highly trained athletes.
Asunto(s)
Hipoxia , Nedocromil , Adulto , Atletas , Difenhidramina/uso terapéutico , Ejercicio Físico/fisiología , Prueba de Esfuerzo , Humanos , Hipoxia/tratamiento farmacológico , Masculino , Nedocromil/uso terapéutico , Oxígeno , Consumo de Oxígeno/fisiología , Adulto JovenRESUMEN
Genetic variation may differentially modify drug and placebo treatment effects in randomized clinical trials. In asthma, although lung function and asthma control improvements are commonplace with placebo, pharmacogenomics of placebo vs. drug response remains unexamined. In a genomewide association study of subjective and objective outcomes with placebo treatment in Childhood Asthma Management Program of nedocromil/budesonide vs. placebo (N = 604), effect estimates for lead single nucleotide polymorphisms (SNPs) were compared across arms. The coughing/wheezing lead SNP, rs2392165 (ß = 0.94; P = 1.10E-07) mapped to BBS9, a gene implicated in lung development that contains a lung function expression quantitative trait locus. The effect was attenuated with budesonide (Pinteraction = 1.48E-07), but not nedocromil (Pinteraction = 0.06). The lead forced vital capacity SNP, rs12930749 (ß = -5.80; P = 1.47E-06), mapped to KIAA0556, a locus genomewide associated with respiratory diseases. The rs12930749 effect was attenuated with budesonide (Pinteraction = 1.32E-02) and nedocromil (Pinteraction = 1.09E-02). Pharmacogenomic analysis revealed differential effects with placebo and drug treatment that could potentially guide precision drug development in asthma.
Asunto(s)
Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Budesonida/uso terapéutico , Nedocromil/uso terapéutico , Efecto Placebo , Niño , Tos/genética , Proteínas del Citoesqueleto/genética , Femenino , Estudio de Asociación del Genoma Completo , Humanos , Masculino , Proteínas Asociadas a Microtúbulos/genética , Medición de Resultados Informados por el Paciente , Pruebas de Farmacogenómica , Polimorfismo de Nucleótido Simple , Ruidos Respiratorios/genética , Resultado del Tratamiento , Capacidad Vital/genéticaRESUMEN
PURPOSE OF REVIEW: To address the current trends of therapeutic mechanisms for treatment of allergic conjunctivitis (AC), based on topical antihistamines and mast cell stabilizers (MCS). RECENT FINDINGS: The antihistamine drug alcaftadine has H4 receptor inverse agonism, anti-inflammatory and MCS activities. The antihistamines levocabastine and azelastine are more effective than placebo in treatment of AC symptoms in randomized controlled trials (RCTs). The topical dual-action antihistamines/MCS olopatadine, azelastine, ketotifen, and epinastine are commonly used in Europe and in the United States for mild subtypes of AC. For the main symptoms of AC, ocular itch and conjunctival hyperemia, epinastine 0.05% was superior to placebo, but equal or more effective than olopatadine 0.1%, while the later was more effective than ketotifen. High concentration olopatadine 0.77% had longer duration of action, better efficacy on ocular itch, and a similar safety profile to low-concentration olopatadine 0.2%. The new formulas of topical dual-action agents present longer duration of action, leading to a decreased frequency of use. SUMMARY: The topical dual-action agents are the most effective agents treating signs and symptoms of mild forms of AC. There is superiority to the high-concentration olopatadine drug over other agents on ocular itch, with prolonged effect when used once-daily.
Asunto(s)
Antialérgicos/uso terapéutico , Conjuntivitis Alérgica/tratamiento farmacológico , Antagonistas de los Receptores Histamínicos/uso terapéutico , Hiperemia/tratamiento farmacológico , Prurito/tratamiento farmacológico , Administración Oftálmica , Benzazepinas/uso terapéutico , Conjuntivitis Alérgica/complicaciones , Cromolin Sódico/uso terapéutico , Dibenzazepinas/uso terapéutico , Humanos , Hiperemia/etiología , Imidazoles/uso terapéutico , Cetotifen/uso terapéutico , Nedocromil/uso terapéutico , Clorhidrato de Olopatadina/uso terapéutico , Ftalazinas/uso terapéutico , Piperidinas/uso terapéutico , Prurito/etiología , Piridinas/uso terapéutico , Pirimidinonas/uso terapéuticoRESUMEN
BACKGROUND: Variation in response to the most commonly used class of asthma controller medication, inhaled corticosteroids, presents a serious challenge in asthma management, particularly for steroid-resistant patients with little or no response to treatment. OBJECTIVE: We applied a systems biology approach to primary clinical and genomic data to identify and validate genes that modulate steroid response in asthmatic children. METHODS: We selected 104 inhaled corticosteroid-treated asthmatic non-Hispanic white children and determined a steroid responsiveness endophenotype (SRE) using observations of 6 clinical measures over 4 years. We modeled each subject's cellular steroid response using data from a previously published study of immortalized lymphoblastoid cell lines under dexamethasone (DEX) and sham treatment. We integrated SRE with immortalized lymphoblastoid cell line DEX responses and genotypes to build a genome-scale network using the Reverse Engineering, Forward Simulation modeling framework, identifying 7 genes modulating SRE. RESULTS: Three of these genes were functionally validated by using a stable nuclear factor κ-light-chain-enhancer of activated B cells luciferase reporter in A549 human lung epithelial cells, IL-1ß cytokine stimulation, and DEX treatment. By using small interfering RNA transfection, knockdown of family with sequence similarity 129 member A (FAM129A) produced a reduction in steroid treatment response (P < .001). CONCLUSION: With this systems-based approach, we have shown that FAM129A is associated with variation in clinical asthma steroid responsiveness and that FAM129A modulates steroid responsiveness in lung epithelial cells.
Asunto(s)
Corticoesteroides/uso terapéutico , Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Asma/genética , Biomarcadores de Tumor/genética , Proteínas de Neoplasias/genética , Budesonida/uso terapéutico , Línea Celular , Niño , Preescolar , Dexametasona/farmacología , Células Epiteliales/metabolismo , Femenino , Humanos , Masculino , Nedocromil/uso terapéutico , Polimorfismo de Nucleótido Simple , Biología de Sistemas , TranscriptomaAsunto(s)
Antiasmáticos/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Asma/tratamiento farmacológico , Eosinofilia Pulmonar/tratamiento farmacológico , Corticoesteroides/uso terapéutico , Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Método Doble Ciego , Humanos , Antagonistas de Leucotrieno/uso terapéutico , Nedocromil/uso terapéutico , Bromuro de Tiotropio/uso terapéutico , Resultado del Tratamiento , Xantina/uso terapéuticoRESUMEN
BACKGROUND: Tracking longitudinal measurements of growth and decline in lung function in patients with persistent childhood asthma may reveal links between asthma and subsequent chronic airflow obstruction. METHODS: We classified children with asthma according to four characteristic patterns of lung-function growth and decline on the basis of graphs showing forced expiratory volume in 1 second (FEV1), representing spirometric measurements performed from childhood into adulthood. Risk factors associated with abnormal patterns were also examined. To define normal values, we used FEV1 values from participants in the National Health and Nutrition Examination Survey who did not have asthma. RESULTS: Of the 684 study participants, 170 (25%) had a normal pattern of lung-function growth without early decline, and 514 (75%) had abnormal patterns: 176 (26%) had reduced growth and an early decline, 160 (23%) had reduced growth only, and 178 (26%) had normal growth and an early decline. Lower baseline values for FEV1, smaller bronchodilator response, airway hyperresponsiveness at baseline, and male sex were associated with reduced growth (P<0.001 for all comparisons). At the last spirometric measurement (mean [±SD] age, 26.0±1.8 years), 73 participants (11%) met Global Initiative for Chronic Obstructive Lung Disease spirometric criteria for lung-function impairment that was consistent with chronic obstructive pulmonary disease (COPD); these participants were more likely to have a reduced pattern of growth than a normal pattern (18% vs. 3%, P<0.001). CONCLUSIONS: Childhood impairment of lung function and male sex were the most significant predictors of abnormal longitudinal patterns of lung-function growth and decline. Children with persistent asthma and reduced growth of lung function are at increased risk for fixed airflow obstruction and possibly COPD in early adulthood. (Funded by the Parker B. Francis Foundation and others; ClinicalTrials.gov number, NCT00000575.).
Asunto(s)
Antiinflamatorios/uso terapéutico , Asma/fisiopatología , Pulmón/fisiología , Administración por Inhalación , Adolescente , Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Budesonida/uso terapéutico , Niño , Preescolar , Femenino , Volumen Espiratorio Forzado , Humanos , Estimación de Kaplan-Meier , Estudios Longitudinales , Pulmón/crecimiento & desarrollo , Masculino , Nedocromil/uso terapéutico , Factores de Riesgo , Factores Sexuales , Espirometría , Adulto JovenRESUMEN
RATIONALE: Most genomic studies of lung function have used phenotypic data derived from a single time-point (e.g., presence/absence of disease) without considering the dynamic progression of a chronic disease. OBJECTIVES: To characterize lung function change over time in subjects with asthma and identify genetic contributors to a longitudinal phenotype. METHODS: We present a method that models longitudinal FEV1 data, collected from 1,041 children with asthma who participated in the Childhood Asthma Management Program. This longitudinal progression model was built using population-based nonlinear mixed-effects modeling with an exponential structure and the determinants of age and height. MEASUREMENTS AND MAIN RESULTS: We found ethnicity was a key covariate for FEV1 level. Budesonide-treated children with asthma had a slight but significant effect on FEV1 when compared with those treated with placebo or nedocromil (P < 0.001). A genome-wide association study identified seven single-nucleotide polymorphisms nominally associated with longitudinal lung function phenotypes in 581 white Childhood Asthma Management Program subjects (P < 10(-4) in the placebo ["discovery"] and P < 0.05 in the nedocromil treatment ["replication"] group). Using ChIP-seq and RNA-seq data, we found that some of the associated variants were in strong enhancer regions in human lung fibroblasts and may affect gene expression in human lung tissue. Genetic mapping restricted to genome-wide enhancer single-nucleotide polymorphisms in lung fibroblasts revealed a highly significant variant (rs6763931; P = 4 × 10(-6); false discovery rate < 0.05). CONCLUSIONS: This study offers a strategy to explore the genetic determinants of longitudinal phenotypes, provide a comprehensive picture of disease pathophysiology, and suggest potential treatment targets.
Asunto(s)
Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Asma/genética , Fibroblastos/efectos de los fármacos , Volumen Espiratorio Forzado/efectos de los fármacos , Volumen Espiratorio Forzado/genética , Nedocromil/uso terapéutico , Factores de Edad , Asma/fisiopatología , Budesonida/uso terapéutico , Niño , Femenino , Regulación de la Expresión Génica , Predisposición Genética a la Enfermedad , Estudio de Asociación del Genoma Completo , Humanos , Estudios Longitudinales , Pulmón/efectos de los fármacos , Masculino , Modelos Teóricos , Fenotipo , Polimorfismo Genético , Factores de TiempoRESUMEN
Diabetic cardiomyopathy is a specific disease process distinct from coronary artery disease and hypertension. The disease features cardiac remodeling stimulated by hyperglycemia of the left ventricle wall and disrupts contractile functions. Cardiac mast cells may be activated by metabolic byproducts resulted from hyperglycermia and then participate in the remodeling process by releasing a multitude of cytokines and bioactive enzymes. Nedocromil, a pharmacologic stabilizer of mast cells, has been shown to normalize cytokine levels and attenuate cardiac remodeling. In this study, we describe the activation of cardiac mast cells by inducing diabetes in normal mice using streptozotocin (STZ). Next, we treated the diabetic mice with nedocromil for 12 weeks and then examined their hearts for signs of cardiac remodeling and quantified contractile function. We observed significantly impaired heart function in diabetic mice, as well as increased cardiac mast cell density and elevated mast cell secretions that correlated with gene expression and aberrant cytokine levels associated with cardiac remodeling. Nedocromil treatment halted contractile dysfunction in diabetic mice and reduced cardiac mast cell density, which correlated with reduced bioactive enzyme secretions, reduced expression of extracellular matrix remodeling factors and collagen synthesis, and normalized cytokine levels. However, the results showed nedocromil treatments did not return diabetic mice to a normal state. We concluded that manipulation of cardiac mast cell function is sufficient to attenuate cardiomyopathy stimulated by diabetes, but other cellular pathways also contribute to the disease process.
Asunto(s)
Diabetes Mellitus Experimental/complicaciones , Cardiomiopatías Diabéticas/etiología , Cardiomiopatías Diabéticas/patología , Mastocitos/patología , Miocardio/patología , Animales , Antiinflamatorios/uso terapéutico , Citocinas/análisis , Cardiomiopatías Diabéticas/tratamiento farmacológico , Cardiomiopatías Diabéticas/fisiopatología , Corazón/efectos de los fármacos , Corazón/fisiopatología , Hiperglucemia/inducido químicamente , Masculino , Mastocitos/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Nedocromil/uso terapéutico , Estreptozocina , Pérdida de Peso/efectos de los fármacosRESUMEN
BACKGROUND: The use of inhaled glucocorticoids for persistent asthma causes a temporary reduction in growth velocity in prepubertal children. The resulting decrease in attained height 1 to 4 years after the initiation of inhaled glucocorticoids is thought not to decrease attained adult height. METHODS: We measured adult height in 943 of 1041 participants (90.6%) in the Childhood Asthma Management Program; adult height was determined at a mean (±SD) age of 24.9±2.7 years. Starting at the age of 5 to 13 years, the participants had been randomly assigned to receive 400 µg of budesonide, 16 mg of nedocromil, or placebo daily for 4 to 6 years. We calculated differences in adult height for each active treatment group, as compared with placebo, using multiple linear regression with adjustment for demographic characteristics, asthma features, and height at trial entry. RESULTS: Mean adult height was 1.2 cm lower (95% confidence interval [CI], -1.9 to -0.5) in the budesonide group than in the placebo group (P=0.001) and was 0.2 cm lower (95% CI, -0.9 to 0.5) in the nedocromil group than in the placebo group (P=0.61). A larger daily dose of inhaled glucocorticoid in the first 2 years was associated with a lower adult height (-0.1 cm for each microgram per kilogram of body weight) (P=0.007). The reduction in adult height in the budesonide group as compared with the placebo group was similar to that seen after 2 years of treatment (-1.3 cm; 95% CI, -1.7 to -0.9). During the first 2 years, decreased growth velocity in the budesonide group occurred primarily in prepubertal participants. CONCLUSIONS: The initial decrease in attained height associated with the use of inhaled glucocorticoids in prepubertal children persisted as a reduction in adult height, although the decrease was not progressive or cumulative. (Funded by the National Heart, Lung, and Blood Institute and the National Center for Research Resources; CAMP ClinicalTrials.gov number, NCT00000575.).
Asunto(s)
Asma/tratamiento farmacológico , Estatura/efectos de los fármacos , Budesonida/farmacología , Glucocorticoides/farmacología , Crecimiento/efectos de los fármacos , Nedocromil/farmacología , Administración por Inhalación , Adolescente , Adulto , Antiasmáticos/farmacología , Antiasmáticos/uso terapéutico , Asma/fisiopatología , Budesonida/uso terapéutico , Niño , Preescolar , Femenino , Estudios de Seguimiento , Glucocorticoides/uso terapéutico , Humanos , Análisis de Intención de Tratar , Masculino , Nedocromil/uso terapéuticoRESUMEN
BACKGROUND: The adverse effects of corticosteroids on bone mineral accretion (BMA) have been well documented. Vitamin D insufficiency, a prevalent condition in the pediatric population, has also been associated with decreased bone mineral density (BMD). OBJECTIVE: We sought to determine whether children with asthma who have lower vitamin D levels are more susceptible to the negative effects of corticosteroids on BMD over time. METHODS: Children aged 5 to 12 years with mild-to-moderate asthma who participated in the Childhood Asthma Management Program were followed for a mean of 4.3 years. Total doses of inhaled corticosteroids and oral corticosteroids (OCSs) were recorded, serum 25-hydroxyvitamin D3 levels were measured at the beginning of the trial, and serial dual-energy x-ray absorptiometry scans of the lumbar spine were performed. Annual BMA rates were defined as follows: [(BMD at 4 years' follow-up - BMD at baseline)/4 years]. RESULTS: BMA was calculated for 780 subjects. In boys baseline vitamin D levels significantly modified the relationship between OCSs and BMA (vitamin D × OCS interaction, P= .023). Stratification by vitamin D levels showed a decrease in BMA with increased use of OCSs in vitamin D-insufficient boys only (P< .001). Compared with vitamin D-sufficient boys, vitamin D-insufficient boys exposed to more than 2 courses of OCSs per year had twice the decrease in BMA rate (relative to boys who were OCS unexposed). CONCLUSIONS: Vitamin D levels significantly modified the effect of OCSs on BMA in boys. Further research is needed to examine whether vitamin D supplementation in children with poorly controlled asthma might confer benefits to bone health.
Asunto(s)
Corticoesteroides/uso terapéutico , Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Calcificación Fisiológica/efectos de los fármacos , Vitamina D/farmacología , Corticoesteroides/efectos adversos , Densidad Ósea/efectos de los fármacos , Budesonida/uso terapéutico , Calcifediol/farmacología , Niño , Preescolar , Femenino , Humanos , Masculino , Nedocromil/uso terapéutico , Resultado del Tratamiento , Vitamina D/sangreRESUMEN
BACKGROUND: Formoterol is a long-acting beta(2)-agonist but because it has a fast onset of action it can also be used as a relief medication. OBJECTIVES: To asses the efficacy and safety of formoterol as reliever therapy in comparison to short-acting beta(2)-agonists in adults and children with asthma. SEARCH STRATEGY: We searched the Cochrane Airways Group Specialised Register and websites of clinical trial registers (for unpublished trial data), and we checked the Food and Drug Administration (FDA) submissions in relation to formoterol. The date of the most recent search was February 2010. SELECTION CRITERIA: Randomised, parallel-arm trials of at least 12 weeks duration in patients of any age and severity of asthma. Studies randomised patients to any dose of as-needed formoterol versus short-acting beta(2)-agonist. Concomitant use of inhaled corticosteroids or other maintenance medication was allowed, as long as this was not part of the randomised treatment regimen. DATA COLLECTION AND ANALYSIS: Two authors independently selected trials for inclusion in the review. Outcome data were extracted by one author and checked by the second author. We sought unpublished data on primary outcomes. MAIN RESULTS: This review includes eight studies conducted in 22,604 participants (mostly adults). Six studies compared formoterol as-needed to terbutaline whilst two studies compared formoterol with salbutamol as-needed. Background maintenance therapy varied across the trials. Asthma exacerbations and serious adverse events showed a direction of treatment effect favouring formoterol, of which one outcome reached statistical significance (exacerbations requiring a course of oral corticosteroids). In patients on short-acting beta(2)-agonists, 117 people out of 1000 had exacerbations requiring oral corticosteroids over 30 weeks, compared to 101 (95% CI 93 to 108) out of 1000 for patients on formoterol as-needed. In patients on maintenance inhaled corticosteroids there were also significantly fewer exacerbations requiring a course of oral corticosteroids on formoterol as-needed (Peto OR 0.75; 95% CI 0.62 to 0.91). There was one death per 1000 people on formoterol or on short-acting beta(2)-agonists. AUTHORS' CONCLUSIONS: In adults, formoterol was similar to short-acting beta(2)-agonists when used as a reliever, and showed a reduction in the number of exacerbations requiring a course of oral corticosteroids. Clinicians should weigh the relatively modest benefits of formoterol as-needed against the benefits of single inhaler therapy and the potential danger of long-term use of long-acting beta(2)-agonists in some patients. We did not find evidence to recommend changes to guidelines that suggest that long-acting beta(2)-agonists should be given only to patients already taking inhaled corticosteroids.There was insufficient information reported from children in the included trials to come to any conclusion on the safety or efficacy of formoterol as relief medication for children with asthma.
Asunto(s)
Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Etanolaminas/uso terapéutico , Adulto , Factores de Edad , Albuterol/uso terapéutico , Budesonida/uso terapéutico , Niño , Cromolin Sódico/uso terapéutico , Fumarato de Formoterol , Humanos , Nedocromil/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Terbutalina/uso terapéuticoAsunto(s)
Asma/genética , Quitina Sintasa/genética , Quitinasas/genética , Predisposición Genética a la Enfermedad , Glicoproteínas/genética , Lectinas/genética , Adipoquinas , Adolescente , Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Budesonida/uso terapéutico , Niño , Preescolar , Proteína 1 Similar a Quitinasa-3 , Femenino , Genotipo , Humanos , Masculino , Estudios Multicéntricos como Asunto , Nedocromil/uso terapéutico , Reacción en Cadena de la Polimerasa , Polimorfismo de Nucleótido Simple , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
BACKGROUND: The course of mild to moderate persistent asthma in children is not clearly established. OBJECTIVE: To determine the rate and predictors for remitting, periodic, and persistent asthma in adolescence. METHODS: The Childhood Asthma Management Program (CAMP) was a 4.3-year randomized, double-masked, multicenter trial in children with mild to moderate persistent asthma that compared continuous therapy with either budesonide or nedocromil, each to placebo, followed by a 4-year observational follow-up period. Asthma activity during the observation period included remitting (no asthma activity in the last year), persistent (asthma activity in every quarter), and periodic asthma (neither remitting nor persistent). RESULTS: Asthma was identified as remitting in 6%, periodic in 39%, and persistent in 55% of the 909 participants, with no effect noted from earlier anti-inflammatory treatment during the CAMP trial. Within all 3 asthma activity categories, improvements in airway hyperresponsiveness, eosinophilia, and asthma morbidity were observed over time. Features at entry into CAMP associated with remitting versus persistent asthma were lack of allergen sensitization and exposure to indoor allergens (odds ratio [OR], 3.23; P < .001), milder asthma (OR, 2.01; P = .03), older age (OR, 1.23; P = .01), less airway hyperresponsiveness (higher log methacholine FEV(1) PC(20) (OR, 1.39; P = .03), higher prebronchodilator FEV(1) percent predicted (OR, 1.05; P = .02), and lower forced vital capacity percent predicted (OR, 0.96; P = .04). CONCLUSION: Remission of asthma in adolescence is infrequent and not affected by 4 years of anti-inflammatory controller therapy. Factors such as sensitization and exposure, low lung function, and airway greater hyperresponsiveness decrease the likelihood of remitting asthma.
Asunto(s)
Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Budesonida/uso terapéutico , Nedocromil/uso terapéutico , Adolescente , Asma/epidemiología , Niño , Preescolar , Método Doble Ciego , Femenino , Humanos , Masculino , Pruebas de Función Respiratoria , Resultado del TratamientoRESUMEN
BACKGROUND: Glucocorticoid function is dependent on efficient translocation of the glucocorticoid receptor (GR) from the cytoplasm to the nucleus of cells. Importin-13 (IPO13) is a nuclear transport receptor that mediates nuclear entry of GR. In airway epithelial cells, inhibition of IPO13 expression prevents nuclear entry of GR and abrogates anti-inflammatory effects of glucocorticoids. Impaired nuclear entry of GR has been documented in steroid-non-responsive asthmatics. We hypothesize that common IPO13 genetic variation influences the anti-inflammatory effects of inhaled corticosteroids for the treatment of asthma, as measured by change in methacholine airway hyperresponsiveness (AHR-PC20). METHODS: 10 polymorphisms were evaluated in 654 children with mild-to-moderate asthma participating in the Childhood Asthma Management Program (CAMP), a clinical trial of inhaled anti-inflammatory medications (budesonide and nedocromil). Population-based association tests with repeated measures of PC20 were performed using mixed models and confirmed using family-based tests of association. RESULTS: Among participants randomized to placebo or nedocromil, IPO13 polymorphisms were associated with improved PC20 (i.e. less AHR), with subjects harboring minor alleles demonstrating an average 1.51-2.17 fold increase in mean PC20 at 8-months post-randomization that persisted over four years of observation (p = 0.01-0.005). This improvement was similar to that among children treated with long-term inhaled corticosteroids. There was no additional improvement in PC20 by IPO13 variants among children treated with inhaled corticosteroids. CONCLUSION: IPO13 variation is associated with improved AHR in asthmatic children. The degree of this improvement is similar to that observed with long-term inhaled corticosteroid treatment, suggesting that IPO13 variation may improve nuclear bioavailability of endogenous glucocorticoids.
Asunto(s)
Asma/tratamiento farmacológico , Asma/genética , Carioferinas/genética , Antiasmáticos/uso terapéutico , Asma/fisiopatología , Hiperreactividad Bronquial/genética , Hiperreactividad Bronquial/fisiopatología , Budesonida/uso terapéutico , Niño , Método Doble Ciego , Variación Genética , Genotipo , Haplotipos , Humanos , Desequilibrio de Ligamiento/genética , Nedocromil/uso terapéutico , Polimorfismo Genético , Polimorfismo de Nucleótido Simple/genéticaRESUMEN
Vascular endothelial growth factor (VEGF) is an angiogenic factor implicated in asthma severity. The objective of the present study was to determine whether VEGF single nucleotide polymorphisms (SNPs) are associated with asthma, lung function and airway responsiveness. The present authors analysed 10 SNPs in 458 white families in the Childhood Asthma Management Program (CAMP). Tests of association with asthma, lung function and airway responsiveness were performed using PBAT software (Golden Helix, Inc. Bozeman, MT, USA; available at www.goldenhelix.com). Family and population-based, revpeated measures analysis of airflow obstruction were conducted. Replication studies were performed in 412 asthmatic children and their parents from Costa Rica. Associations with asthma, lung function and airway responsiveness were observed in both cohorts. SNP rs833058 was associated with asthma in both cohorts. This SNP was also associated with increased airway responsiveness in both populations. An association of rs4711750 and its haplotype with forced expiratory volume in 1 s (FEV(1))/forced vital capacity (FVC) ratio in both cohorts was observed. Longitudinal analysis in CAMP confirmed an association of rs4711750 with FEV(1)/FVC decline over approximately 4.5 yrs of observation. VEGF polymorphisms are associated with childhood asthma, lung function and airway responsiveness in two populations, suggesting that VEGF polymorphisms influence asthma susceptibility, airflow obstruction and airways responsiveness.
Asunto(s)
Asma/genética , Asma/fisiopatología , Factor A de Crecimiento Endotelial Vascular/genética , Adolescente , Corticoesteroides/administración & dosificación , Corticoesteroides/uso terapéutico , Antiasmáticos/administración & dosificación , Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Pruebas de Provocación Bronquial , Niño , Costa Rica , Método Doble Ciego , Femenino , Volumen Espiratorio Forzado , Genotipo , Haplotipos , Humanos , Masculino , Nedocromil/administración & dosificación , Nedocromil/uso terapéutico , Fenotipo , Placebos , Polimorfismo de Nucleótido Simple , Análisis de Regresión , Pruebas de Función Respiratoria , Programas Informáticos , Capacidad Vital , Población Blanca/genéticaRESUMEN
OBJECTIVES: To determine whether long-term, continuous use of inhaled anti-inflammatory medications affects asthma outcomes in children with mild to moderate asthma after use is discontinued. STUDY DESIGN: Of the 1041 participants in the Childhood Asthma Management Program randomized clinical trial, 941 (90%) were followed to determine whether 4.3 years of twice-daily budesonide or nedocromil administration (each compared with placebo) affected subsequent asthma outcomes during a 4.8-year posttrial period in which treatment was managed by the participants' physicians. RESULTS: The groups treated continuously during the trial with either budesonide or nedocromil did not differ from the group given placebo in terms of lung function, control of asthma, or psychological status at the end of 4.8 years of posttrial follow-up. However, the decreased mean height in the budesonide group relative to the placebo group at the end of the trial (1.1 cm; P = .005) remained statistically significant (0.9 cm; P = .01) after an additional 4.8 years and was more pronounced in girls (1.7 cm; P = .001) than in boys (0.3 cm; P = .49). Participants in all groups used inhaled corticosteroids during 30% of the posttrial period. CONCLUSIONS: Clinically meaningful improvements in the control of asthma and in airway responsiveness achieved during continuous treatment with inhaled corticosteroids do not persist after continuous treatment is discontinued.
Asunto(s)
Antiinflamatorios/uso terapéutico , Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Budesonida/uso terapéutico , Nedocromil/uso terapéutico , Adolescente , Estatura , Utilización de Medicamentos , Urgencias Médicas , Femenino , Estudios de Seguimiento , Volumen Espiratorio Forzado , Humanos , Masculino , Nebulizadores y Vaporizadores , Evaluación de Resultado en la Atención de Salud , Prednisona/uso terapéutico , Índice de Severidad de la Enfermedad , Factores Sexuales , Capacidad VitalAsunto(s)
Asma/diagnóstico , Pulmón/metabolismo , Mastocitos/patología , Mastocitosis Sistémica/diagnóstico , Dolor Abdominal , Acetatos/uso terapéutico , Antiasmáticos/uso terapéutico , Antiinflamatorios/uso terapéutico , Asma/complicaciones , Asma/fisiopatología , Asma/terapia , Budesonida/uso terapéutico , Permeabilidad Capilar/efectos de los fármacos , Tos , Ciclopropanos , Diarrea , Disnea , Femenino , Humanos , Pulmón/efectos de los fármacos , Pulmón/patología , Mastocitos/efectos de los fármacos , Mastocitosis Sistémica/complicaciones , Mastocitosis Sistémica/fisiopatología , Mastocitosis Sistémica/terapia , Persona de Mediana Edad , Nedocromil/uso terapéutico , Quinolinas/uso terapéutico , SulfurosRESUMEN
SCOPE OF THE REVIEW: Our knowledge of the multifunctional nature of airway smooth muscle (ASM) has expanded rapidly in the last decade, but the underlying molecular mechanisms and how current therapies for obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), affect these are still being elucidated. Our current knowledge has built on the pharmacology of human ASM contraction and relaxation established prior to that and which is reviewed in detail elsewhere in this issue. The advent of methods to isolate and culture ASM cells, especially human ASM cells, has made it possible to study how they may contribute to airway remodelling through their synthetic, proliferative, and migratory capacities. Now the underlying molecular mechanisms of ASM growth factor secretion, extracellular matrix (ECM) production, proliferation and migration, as well as contraction and relaxation, are being determined. A complex network of signalling pathways leading to gene transcription in ASM cells permits this functional plasticity in healthy and diseased airways. This review is an overview of the effects of current therapies, and some of those in development, on key signalling pathways and transcription factors involved in these ASM functions.
Asunto(s)
Antiasmáticos/farmacología , Asma/tratamiento farmacológico , Músculo Liso/efectos de los fármacos , Sistema Respiratorio/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Activación Transcripcional/efectos de los fármacos , Agonistas Adrenérgicos beta/farmacología , Agonistas Adrenérgicos beta/uso terapéutico , Animales , Antiasmáticos/uso terapéutico , Asma/metabolismo , Antagonistas Colinérgicos/farmacología , Antagonistas Colinérgicos/uso terapéutico , Cromolin Sódico/farmacología , Cromolin Sódico/uso terapéutico , Quimioterapia Combinada , Glucocorticoides/farmacología , Glucocorticoides/uso terapéutico , Humanos , Antagonistas de Leucotrieno/farmacología , Antagonistas de Leucotrieno/uso terapéutico , Músculo Liso/metabolismo , Músculo Liso/fisiología , Nedocromil/farmacología , Nedocromil/uso terapéutico , Sistema Respiratorio/metabolismo , Transducción de Señal/fisiología , Factores de Transcripción/metabolismoRESUMEN
BACKGROUND: Weak and inconsistent correlations between measurements of asthma health status suggest that the disease is composed of nonoverlapping components. OBJECTIVE: Factor analysis was used to explore the relationships between measures of asthma morbidity and to identify heterogeneous components of asthma health status in children 5 to 12 years old. Results were compared across time (baseline and 48-month visit) and treatment arms. METHODS: Analyses were conducted in 7 different study windows in a database from a large clinical trial of children with mild to moderate asthma (n = 1041). Measurements of lung function, symptoms, and health care utilization from daily diary cards, serum IgE levels, total eosinophil count, skin test positivity, and airway hyperresponsiveness were included. Data on fractional exhaled nitric oxide and sputum eosinophil cationic protein were included in a subgroup of patients. RESULTS: In each of the study windows, factor analysis identified 5 factors that explained between 50% and 60% of the common variance. Factors identified included (1) inflammatory markers, (2) symptoms/medication use, (3) asthma exacerbations, and measures of lung function, which subdivided into (4) FEV(1) and forced vital capacity, and (5) bronchodilator response and the FEV(1)/forced vital capacity ratio. Exploratory analyses suggest that fractional exhaled nitric oxide account for the atopy/inflammatory marker factor, and sputum measurements account for a sixth, separate factor. CONCLUSION: The consistent identification of a 5-factor structure across time and treatment arms suggests that each of these factors provides independent information in the assessment of asthma.